



MONTANA HEALTHCARE PROGRAMS NOTICE

February 2, 2022

Pharmacy, Mid-Level, IHS, Tribal 638, Physician Providers

Effective March 7, 2022

Dose Limitations for Gabapentinoids

Effective March 7, 2022, Montana Healthcare Programs will implement limits on daily gabapentin and pregabalin doses to reflect Food and Drug Administration (FDA) approved maximum daily dosages. Beginning March 7, 2022, claims billed for gabapentin doses over 3600mg per day or pregabalin (Lyrica®) doses over 600mg per day will deny at the pharmacy point of sale.

Montana Healthcare Programs limits medication coverage to FDA approved indications and dosages. Furthermore, in December 2019, the [FDA issued a warning](#) regarding the increased risk of abuse, misuse, and adverse events, including severe respiratory depression, at higher doses of gabapentinoids.

The maximum daily dosage limits will be added to the duplicate therapy (multiple strengths or multiple gabapentinoids) limits already in place.

Contact Information

Drug Prior Authorization Unit
Mountain-Pacific Quality Health
P.O. Box 5119
Helena, MT 59604
406-443-6002 or 1-800-395-7961 (Phone)
406-513-1928 or 1-800-294-1350 (Fax)

For questions regarding this policy, please contact Shannon Sexauer, PharmD, Medicaid Pharmacist, at (406) 444-5951 or shannon.sexauer@mt.gov or Dani Feist, Pharmacy Program Officer, at (406) 444-2738 or dfeist@mt.gov.

For claims questions or additional information, contact Montana Provider Relations at (800) 624-3958 or (406) 442-1837 or email [Montana Provider Relations Helpdesk](#).

[Visit the Montana Healthcare Programs Provider Information website at https://medicaidprovider.mt.gov.](https://medicaidprovider.mt.gov)